ABSTRACT
An excessive immune response contributes to SARS-CoV, MERS-CoV and SARS-CoV-2 pathogenesis and lethality, but the mechanism remains unclear. In this study, the N proteins of SARS-CoV, MERS-CoV and SARS-CoV-2 were found to bind to MASP-2, the key serine protease in the lectin pathway of complement activation, resulting in aberrant complement activation and aggravated inflammatory lung injury. Either blocking the N protein:MASP-2 interaction or suppressing complement activation can significantly alleviate N protein-induced complement hyper-activation and lung injury in vitro and in vivo. Complement hyper-activation was also observed in COVID-19 patients, and a promising suppressive effect was observed when the deteriorating patients were treated with anti-C5a monoclonal antibody. Complement suppression may represent a common therapeutic approach for pneumonia induced by these highly pathogenic coronaviruses. One Sentence SummaryThe lectin pathway of complement activation is a promising target for the treatment of highly pathogenic coronavirus induced pneumonia.
ABSTRACT
Objective To discuss the effect of Human Immunoglobulin for Intravenous Injection in the treatment of neonatal pneumonia treatment and intervention. Methods 100 cases of newborns in our hospital from July 2015 to 2016 to receive the treatment of infectious pneumonia patients, and were randomly divided into control group and observation group, 50 cases in each group. The control group used routine treatment, the observation group on the basis of intravenous immunoglobulin and take corresponding nursing measures. The treatment were compared between the two groups of the total efficiency of disappearance of hospitalization time and pulmonary rales and difficulty breathing time. Results In the control group than the treatment in the observation group the total efficiency significantly comparison between the two groups of children have statistical significance(P<0.05); disappeared in the observation group hospitalization time and pulmonary rales and dyspnea was significantly better on time According to the group, there were significant differences between the two groups have statistical significance(P<0.05). Conclusion The use of Human Immunoglobulin for Intravenous Injection on the treatment of neonatal pneumonia, can effectively promote the treatment efficiency, and is helpful to the patient's recovery, worthy of promotion in clinical use.